Biochemical Characterization of In vitro Reconstituted Biologically Active Recombinant Shiga Toxin
- 15 March 2019
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 26 (3) , 227-234
Abstract
Background: Shiga toxins comprise a family of related proteins produced by bacteria Shigella dysenteriae and some strains of Escherichia coli that cause severe clinical manifestations. Severe Shiga toxin intoxication results in Haemolytic-Uremic Syndrome (HUS), up to 50% of HUS patients manifest some degree of renal failure and ~10% of such cases develop permanent renal failure or death. Objective: In present research work production of biologically active rStx from non-toxic rStxA and rStxB subunits were established that can be used in many biomedical applications.Methods: Purification of Shiga toxin from bacteria is a multistep time consuming process resulting in low yield. To overcome this problem, the rStxA and rStxB protein were separately cloned and expressed in E. coli host and purified through affinity chromatography. GST pull-down assay was performed for interaction study between rStxA and pentameric rStxB. The affinity between A and B subunits of reconstituted recombinant Shiga toxin (AB5) was determined by SPR. The biological activity of the toxin was confirmed in Vero cells and mouse lethality assay.Results: The yield of GST-StxA and His6X-StxB obtained after affinity chromatography was estimated to 2 and 5 mg/l, respectively. Samples analyzed in pull down assay revealed two bands of ~58 kDa (rStxA) and ~7.7 kDa (rStxB) on SDS-PAGE. Affinity was confirmed through SPR with KD of 0.85 pM. This rStx produced from 1:5 molar ratio found to be cytotoxic in Vero cell line and resulted lethality in mouse.Conclusions: Large scale production of rStx using the method can facilitate screening and evaluation of small molecule inhibitors for therapeutics development.Keywords
This publication has 24 references indexed in Scilit:
- Shiga toxin and its use in targeted cancer therapy and imagingMicrobial Biotechnology, 2010
- Protection against Shiga Toxin-ProducingEscherichia coliInfection by Transcutaneous Immunization with Shiga Toxin Subunit BClinical and Vaccine Immunology, 2008
- Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2☆Vaccine, 2006
- Protection against Shiga Toxin 1 Challenge by Immunization of Mice with Purified Mutant Shiga Toxin 1Infection and Immunity, 2003
- Reconstitution of active recombinant Shiga toxin (Stx)1 from recombinant Stx1-A and Stx1-B subunits independently produced byE. coliclonesFEMS Microbiology Letters, 1999
- Shiga Toxin Attacks Bacterial Ribosomes as Effectively as Eucaryotic RibosomesBiochemistry, 1998
- Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagicEscherichia coliO157:H7FEMS Immunology & Medical Microbiology, 1997
- USE OF SURFACE PLASMON RESONANCE TO PROBE THE EQUILIBRIUM AND DYNAMIC ASPECTS OF INTERACTIONS BETWEEN BIOLOGICAL MACROMOLECULESAnnual Review of Biophysics, 1997
- Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomesEuropean Journal of Biochemistry, 1988
- Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.Journal of Experimental Medicine, 1984